SV2008002612A - Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo - Google Patents

Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo

Info

Publication number
SV2008002612A
SV2008002612A SV2006002612A SV2006002612A SV2008002612A SV 2008002612 A SV2008002612 A SV 2008002612A SV 2006002612 A SV2006002612 A SV 2006002612A SV 2006002612 A SV2006002612 A SV 2006002612A SV 2008002612 A SV2008002612 A SV 2008002612A
Authority
SV
El Salvador
Prior art keywords
oral
approximately
delayed
dosage form
hours
Prior art date
Application number
SV2006002612A
Other languages
English (en)
Spanish (es)
Inventor
Syed M Shah
Mahdi B Fawzi
Ramarao Chatlapalli
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2008002612A publication Critical patent/SV2008002612A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SV2006002612A 2005-07-15 2006-07-13 Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo SV2008002612A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69962305P 2005-07-15 2005-07-15

Publications (1)

Publication Number Publication Date
SV2008002612A true SV2008002612A (es) 2008-08-29

Family

ID=37669348

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2006002612A SV2008002612A (es) 2005-07-15 2006-07-13 Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo

Country Status (20)

Country Link
US (1) US20070014859A1 (https=)
EP (1) EP1904040A2 (https=)
JP (1) JP2009501233A (https=)
KR (1) KR20080025405A (https=)
CN (1) CN101247791A (https=)
AR (1) AR054833A1 (https=)
AU (1) AU2006270315A1 (https=)
BR (1) BRPI0613484A2 (https=)
CA (1) CA2612960A1 (https=)
CR (1) CR9626A (https=)
EC (1) ECSP088106A (https=)
GT (1) GT200600307A (https=)
IL (1) IL188313A0 (https=)
MX (1) MX2008000666A (https=)
NO (1) NO20080088L (https=)
PE (1) PE20070192A1 (https=)
RU (1) RU2007148195A (https=)
SV (1) SV2008002612A (https=)
TW (1) TW200740427A (https=)
WO (1) WO2007011619A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
DE602006010343D1 (de) * 2005-03-31 2009-12-24 Wyeth Corp Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
US20080175873A1 (en) * 2005-06-02 2008-07-24 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2629609A1 (en) * 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
TR200909798T1 (tr) * 2007-07-12 2010-05-21 Dr. Reddy's Laboratories Ltd. O-desmetilvenlafaksin.
CA2702664A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0722303A2 (pt) * 2007-12-10 2014-04-22 Wyeth Llc O-desmatil-venlafaxina para tratar transtorno depressivo maior
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN101716168B (zh) * 2008-10-09 2014-09-17 北京德众万全医药科技有限公司 一种含有去甲文拉法新的盐的药物组合物及其制备方法
EP2191822A1 (en) 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
MX2012010659A (es) 2010-03-31 2013-03-05 Wockhardt Ltd Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales.
CN102085197B (zh) * 2010-12-14 2013-08-14 北京万生药业有限责任公司 一种文拉法辛缓释制剂及其制备方法
KR20140030156A (ko) 2011-04-12 2014-03-11 루핀 리미티드 방출-조절되는 데스벤라팍신 약학 조성물
CN111008356B (zh) * 2019-11-13 2023-06-16 成都理工大学 一种基于WTSVD算法扣除背景的γ能谱集分析方法
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
ES2277030T3 (es) * 2003-05-02 2007-07-01 Dexcel Ltd. Formulacion en comprimidos de venlafaxina de liberacion prolongada.
AU2005212166A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate O-desmethylvenlafaxine salts and uses thereof
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology

Also Published As

Publication number Publication date
WO2007011619A2 (en) 2007-01-25
MX2008000666A (es) 2008-03-13
US20070014859A1 (en) 2007-01-18
EP1904040A2 (en) 2008-04-02
BRPI0613484A2 (pt) 2016-11-16
CR9626A (es) 2008-04-10
KR20080025405A (ko) 2008-03-20
NO20080088L (no) 2008-04-02
CA2612960A1 (en) 2007-01-25
GT200600307A (es) 2008-04-24
WO2007011619A3 (en) 2007-06-21
JP2009501233A (ja) 2009-01-15
RU2007148195A (ru) 2009-08-20
PE20070192A1 (es) 2007-03-16
CN101247791A (zh) 2008-08-20
ECSP088106A (es) 2008-02-20
IL188313A0 (en) 2008-04-13
TW200740427A (en) 2007-11-01
AU2006270315A1 (en) 2007-01-25
AR054833A1 (es) 2007-07-18

Similar Documents

Publication Publication Date Title
SV2008002612A (es) Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
BRPI0515316A (pt) compostos de imidazoquinolina
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
BR0107869A (pt) Composições farmacêuticas eletrogiradas
RU2009120990A (ru) Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
CR10732A (es) Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
MX2008004734A (es) Composicion rica en leucina.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
PA8586301A1 (es) Formulaciones de liberacion prolongada en forma de suspension
UA87841C2 (ru) Композиция, которая содержит амброксол, для местного применения
MX2007000117A (es) Una composicion de combinacion.
WO2004022002A3 (en) Combined immediate release and extended release analgesic composition
TW200509863A (en) Irradiation device for medical use
BRPI0508680A (pt) composição de resfriamento natural, composição flavorizante, produto pronto-para-consumo, e, uso de uma composição
EA200700055A1 (ru) Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía